Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with temozolomide for recurrent glioma
ChiCTR2100046653Phase 4Recruiting
- Sponsor
- Anhui Cancer Hospital
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Rivoceranib and temozolomide in glioma (2 arms), sponsored by Anhui Cancer Hospital. Primary endpoints: Short diameter of lesion, Progression-free survival (PFS) and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
Rivoceranibtemozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2100046653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046653.